Gilead price target raised to $103 from $95 at Raymond James

Raymond James raised the firm’s price target on Gilead (GILD) to $103 from $95 and keeps an Outperform rating on the shares. The firm called Gilead’s Q3 earnings beat “solid,” citing strong continued growth in core HIV business and early signs of strength for Livdelzi in PBC. However, the firm added that Gilead’s cell therapy business showed weakness, down 7% quarter-over-quarter for combined worldwide sales of Tecartus and Yescarta.